Skip to main content
Panacea Biotec Ltd. logo

Panacea Biotec Ltd. — Investor Relations & Filings

Ticker · PANACEABIO ISIN · INE922B01023 LEI · 3358001FA81ZQYDLO796 BSE.NS Manufacturing
Open in API
Filings indexed 797 across all filing types
Latest filing 2026-05-29 Board/Management Inform…
Country IN India
Listing BSE.NS PANACEABIO

About Panacea Biotec Ltd.

https://www.panaceabiotec.com

Panacea Biotec Ltd. is a research-driven health management company specializing in the development, manufacturing, and marketing of vaccines, biopharmaceuticals, and pharmaceutical formulations. The organization focuses on therapeutic segments including organ transplantation, nephrology, oncology, diabetes, and pain management. Its vaccine portfolio supports global immunization initiatives, addressing diseases such as polio and hepatitis B through partnerships with international health agencies. The company operates integrated research and development centers and manufacturing facilities that adhere to international quality standards. Panacea Biotec emphasizes the creation of innovative drug delivery systems and complex generics to improve patient outcomes. Its operations are characterized by a commitment to biotechnology-led medical solutions and the production of affordable, high-quality therapeutic products for diverse global markets.

Recent filings

Filing Released Lang Actions
We would like to inform you that the Board of Directors of the Company''s material wholly owned subsidiary, Panacea Biotec Pharma Ltd., has in its meeting held today i.e. 29.05.2026 , inter-alia, ....
Board/Management Information Classification · 95% confidence The document is a formal disclosure under SEBI LODR Regulation 30 announcing the appointment and re-appointment of independent directors at the company’s subsidiary. It provides detailed director profiles, terms, and regulatory references. This clearly matches an announcement of changes in the company’s board of directors, which falls under the Board/Management Information category.
2026-05-29 English
Please find enclosed Secretarial Compliance Report duly issued by R&D Company Secretaries, Practicing Company Secretaries for the financial year ended March 31, 2026.
Regulatory Filings Classification · 85% confidence The document is titled “Secretarial Compliance Report under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015” and comprises a third-party attestation by company secretaries verifying statutory and regulatory compliance for the financial year ended March 31, 2026. It does not contain substantive financial statements, management discussion, or a narrative investor presentation. Instead, it is an official compliance certification submitted to stock exchanges. Under the “Certification Rule,” such attestation letters and compliance certificates fall under the general regulatory filings category (RNS).
2026-05-29 English
General Updates
Board/Management Information Classification · 95% confidence The document is an official disclosure under SEBI (Listing Obligations and Disclosure Requirements) Regulation 30, announcing the appointment and reappointment of non-executive independent directors to the Board (of the subsidiary). It provides details on board composition changes without presenting any financial statements or other report content. This clearly falls under Board/Management Information.
2026-05-29 English
The Board Meeting to be held on 29/05/2026 has been revised to 30/05/2026 The Board Meeting to be held on 29/05/2026 has been revised to 30/05/2026
Regulatory Filings Classification · 82% confidence The document is a notice to stock exchanges under SEBI Listing Obligations about the postponement and rescheduling of a Board meeting date to approve audited financial results and related compliance (trading window closure). It does not contain financial data or the report itself, nor does it announce a director change, dividend declaration, or management changes. It is a general regulatory announcement/fallback notification, best fitting the Regulatory Filings (RNS) category.
2026-05-26 English
Panacea Biotec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Standalone and Consolidated ....
Regulatory Filings Classification · 80% confidence The document is an exchange filing under SEBI LODR Regulation 29 notifying the stock exchanges of a scheduled Board meeting to consider and approve audited financial results. It does not contain actual financial statements or results, nor does it announce publication of a report; it is a general regulatory announcement/disclosure. Therefore, it falls under the catch-all Regulatory Filings category (RNS).
2026-05-23 English
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges and depositories reporting the details of shares dematerialized during April 2026. It references compliance with SEBI regulations and includes a certificate from the registrar and share transfer agent confirming the dematerialized shares. The content is an official notification about share dematerialization status, not a financial report, earnings release, or management discussion. The document length is short (2841 characters) and it serves as a regulatory compliance update. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-05-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.